Do you want to read an article? Please log in or register.
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study
Gastrointestinal Cancer
Related content
Gastrointestinal Cancer
Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Lancet Oncol
Modest DP, Fakih M, Salvatore L, Esaki T, Lopez-Bravo DP, Taieb J, Karamouzis M, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Tran Q, Chan E, Chao J, Majer IM, Pietrantonio F
doi: 10.1016/S1470-2045(25)00352-3
Gastrointestinal Cancer
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Int J Cancer
Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, de Buhr R, Polata S, Gerger A, Zehrer V, Amann A, Göhler T, Serrer L, Schröder J, Semsek D, Köhler A, Stübs P, Prager G, Siebenbach HU, Schuch A, Marschner N
doi: 10.1002/ijc.70139
RECOMMENDED
Breast Cancer
Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Clin Cancer Res
Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G
doi: 10.1158/1078-0432.CCR-24-1724
Lung, Respiratory and Thoracic Cancer
Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial
Lung Cancer
Liu T, He J, Wang Y, Yang Y, Zhang L, Shi M, Liu J, Sun D, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Huang Y, Fang W, Yang Y, Zhao Y, Zhang L
doi: 10.1016/j.lungcan.2025.108108
Skin Cancer
Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial
Ann Oncol
Ten Ham RMT, Rohaan MW, Egeler M, Menezes R, Holz Borch T, Kessels R, Jedema I, Nuijen B, Nijenhuis C, van de Poll-Franse LV, Geukes Foppen MH, Lindenberg M, Mansfield Noringriis I, Monberg TJ, Donia M, van Harten W, Svane IM, Haanen JBAG, Retèl VP
doi: 10.1016/j.annonc.2025.06.005
Breast Cancer
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial
J Natl Cancer Inst
Wortelboer N, Kent S, Blommestein HM, van Ommen-Nijhof A, van der Noort V, van den Pol E, Páez CG, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van de Mheen CVS, Tol J, Driel CST, Vrijaldenhoven S, van Leeuwen-Stok AE, Sonke GS, Jager A, Konings IR
doi: 10.1093/jnci/djaf334
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Further Publications
ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY
Ann Oncol
Toss A, Blondeaux E, Tenedini E, Bonamici L, Graffeo R, Livraghi L, Villarreal-Garza C, Molho RB, Kwong A, Balmana J, Wildiers H, Agostinetto E, Phillips KA, Pogoda K, Renaud T, Rousset-Jablonski C, Ferrari A, Moore HCF, Peccatori FA, Paluch-Shimon S, Fruscio R, Micheri C, Wong SM, Cui W, Vernieri C, Lee M, De Marchis L, Couch FJ, Del Mastro L, Puglisi F, Meireles PA, Kemp Z, Matikas A, Plichta J, Del Pilar Estevez-Diz M, Di Meglio A, Cichowska-Cwalinska N, Gianni C, Yerushalmi R, Sanchez-Bayona R, Mrinakova B, Matos L, Bianchini G, Caleffi M, Krivokuca A, Abdou Y, Mariño-Mariño M, Parokonnaya A, Okano M, Antone N, Saavedra C, Sonnenblick A, Duchnowska R, Pais HL, Harbeck N, Cortesi L, Delucchi V, De Angelis C, Lambertini M
doi: 10.1016/j.annonc.2025.11.004
Further Publications
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)
Eur J Cancer
Maglietta G, Damato A, Finotto S, Mandarà M, Tamberi S, Grisanti S, Brighenti M, Tiseo M, Montesarchio V, Catino A, Gelsomino F, Giovanardi F, Antonuzzo L, Romagnani A, Gervasi E, Di Maio M, Pinto C
doi: 10.1016/j.ejca.2025.115296